Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Интраназальный флутиказона пропионат в фармакотерапии аллергического ринита
Интраназальный флутиказона пропионат в фармакотерапии аллергического ринита
Астафьева Н.Г., Гамова И.В., Кобзев Д.Ю., Перфилова И.А., Удовиченко Е.Н., Алешина Л.В. Интраназальный флутиказона пропионат в фармакотерапии аллергического ринита. Consilium Medicum. 2021; 23 (9): 421–429. DOI: 10.26442/20751753.2021.9.201059
DOI: 10.26442/20751753.2021.9.201059
________________________________________________
DOI: 10.26442/20751753.2021.9.201059
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Ринит является одним из самых распространенных заболеваний и как зонтичный диагноз используется для пациентов с разными клиническими фенотипами заболевания (аллергический, неаллергический, инфекционный и др.). Признавая высокое социально-экономическое бремя болезни и сложности выбора оптимальной терапии, важно акцентировать внимание на междисциплинарных взаимодействиях, что нашло отражение в современных клинических рекомендациях, созданных экспертами ARIA, EAACI, EPOS и национальными профессиональными обществами. Пациенты с симптомами ринита нередко занимаются самолечением, пользуются советами работников аптек, получают рекомендации врачей первичного звена в амбулаторной практике; лишь часть больных попадают к специалистам (ЛОР или аллерголог-иммунолог), поэтому при многих клинических ситуациях критерии контроля болезни (симптомы, качество жизни, объективные измерения) не достигаются. В настоящее время международными сообществами разработаны инновационные терапевтические подходы, основанные на знании фенотипов/эндотипов ринита для достижения контроля. Врачам как первичной, так и специализированной помощи предлагается использовать ступенчатую терапию. В современном подходе к лечению на основании контроля симптомов заболевания самыми эффективными противовоспалительными препаратами для длительного контроля ринита, особенно среднетяжелого/тяжелого течения, считаются интраназальные глюкокортикостероиды (ИнГКС). Хорошо доказанная эффективность ИнГКС и их преимущества перед другими классами препаратов делают их терапией 1-й линии в лечении аллергического ринита (уровень доказательности А), а также препаратами выбора для неаллергического ринита, риносинуситов. В представленном обзоре обсуждается один из востребованных ИнГКС – флутиказона пропионат, который в течение многих лет является основой лечения аллергического ринита.
Ключевые слова: аллергический ринит, фармакотерапия, интраназальные кортикостероиды, флутиказона пропионат
Keywords: allergic rhinitis, pharmacotherapy, intranasal corticosteroids, fluticasone propionate
Ключевые слова: аллергический ринит, фармакотерапия, интраназальные кортикостероиды, флутиказона пропионат
________________________________________________
Keywords: allergic rhinitis, pharmacotherapy, intranasal corticosteroids, fluticasone propionate
Полный текст
Список литературы
1. Wise SK, Lin SY, Toskala E, et al. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108-352. DOI:10.1002/alr.22073
2. Bousquet J, Schünemann HJ, Togias A, et al; Allergic Rhinitis and Its Impact on Asthma Working Group. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70-80.e3. DOI:10.1016/j.jaci.2019.06.049
3. Bousquet J, Schunemann HJ, Hellings PW, et al. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016;138(2):367-74. DOI:10.1016/j.jaci.2016.03.025
4. Bousquet J, Schünemann HJ, Hellings PW, et al; MASK study group. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016;138(2):367-74.e2. DOI:10.1016/j.jaci.2016.03.025
5. Fokkens W, Lund V, Hopkins HP, et al. EPOS2020: European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl. S29):1-464.
6. Global atlas of allergic rhinitis and chronic rhinosinusitis. Ed. CA Akdis, PW Hellings, I Agache, et al. Zurich, Switzerland: European Academy of Allergy and Clinical Immunology, 2015.
7. Papadopoulos NG, Bernstein JA, Demoly P, et al. Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report. Allergy. 2015;70(5):474-94. DOI:10.1111/all.12573
8. Brożek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines – 2016 Revision. J Allergy Clin Immunol. 2017;140(4):950-8. DOI:10.1016/j.jaci.2017.03.050
9. Аллергический ринит. Федеральные клинические рекомендации. Российский аллергологический журнал. 2018;4:43-53 [Allergicheskii rinit. Federal'nye klinicheskie rekomendatsii. Rossiiskii allergologicheskii zhurnal. 2018;4:43-53 (in Russian)].
10. Аллергический ринит. Клинические рекомендации. Российская ассоциация аллергологов и клинических иммунологов; Национальная медицинская ассоциация оториноларингологов; Союз педиатров России. 2021. Режим доступа: https://www.pediatr-russia.ru/information/klin-rek/proekty-klinicheskikh-rekomendatsiy. Ссылка активна на 11.08.2021 [Allergic rhinitis. Clinical guidelines. Russian Association of Allergists and Clinical Immunologists; National Medical Association of Otorhinolaryngologists; Union of Pediatricians of Russia. 2021. Available at: https://www.pediatr-russia.ru/information/klin-rek/proekty-klinicheskikh-rekomendatsiy. Accessed: 11.08.2021 (in Russian)].
11. Астафьева Н.Г., Кобзев Д.Ю., Гамова И.В., и др. Многоликий ринит: современный взгляд на диагностику и алгоритм лечения. Лечащий врач. 2018;4:7-18 [Astaf'eva NG, Kobzev DIu, Gamova IV, et al. Mnogolikii rinit: sovremennyi vzgliad na diagnostiku i algoritm lecheniia. Lechashchii vrach. 2018;4:7-18 (in Russian)].
12. Bousquet J, Schunemann HJ, Fonseca J, et al. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy. 2015;70:1372-92.
13. Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl. S29):1-464. DOI:10.4193/Rhin20.600
14. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl. 86):8-160. DOI:10.1111/j.1398-9995.2007.01620.x
15. Settipane RA, Kaliner MA. Nonallergic rhinitis. Am J Rhinol Allergy. 2013;27(Suppl. 1):S48-51.
16. Hellings PW, Klimek L, Cingi C, et al. Non-allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2017;72(11):1657-65. DOI:10.1111/all.13200
17. Poddighe D, Gelardi M, Licari A, et al. Non-allergic rhinitis in children: Epidemiological aspects, pathological features, diagnostic methodology and clinical management. World J Methodol. 2016;6(4):200-13. DOI:10.5662/wjm.v6.i4.200
18. Астафьева Н.Г., Удовиченко Е.Н., Гамова И.В., и др. Аллергические и неаллергические риниты: сравнительная характеристика (часть 1). Лечащий врач. 2013;4:10-2 [Astaf'eva NG, Udovichenko EN, Gamova IV, et al. Allergicheskie i neallergicheskie rinity: sravnitel'naia kharakteristika (chast' 1). Lechashchii vrach. 2013;4:10-2 (in Russian)].
19. Шамкина П.А., Кривопалов А.А., Рязанцев С.В., и др. Эпидемиология хронических риносинуситов. Современные проблемы науки и образования. 2019;3:152. Режим доступа: https://science-education.ru/ru/article/view?id=28891. Ссылка активна на 09.08.2021 [Shamkina PA, Krivopalov AA, Ryazantsev SV, et al. Epidemiology of chronic rhinosinusitis. Sovremennye problemy nauki i obrazovaniia. 2019;3:152. Available at: https://science-education.ru/ru/article/view?id=28891. Accessed: 09.08.2021 (in Russian)].
20. Острый риносинусит: клинические рекомендации. Под ред. А.С. Лопатина. М., 2017 [Acute rhinosinusitis: clinical guidelines. Ed. AS Lopatin. Moscow, 2017 (in Russian)].
21. Тюфилин Д.С., Деев И.А., Кобякова О.С., и др. Контроль аллергического ринита: современные инструменты оценки. Бюллетень сибирской медицины. 2019;18(2):262-71 [Tiufilin DS, Deev IA, Kobiakova OS, et al. Kontrol' allergicheskogo rinita: sovremennye instrumenty otsenki. Biulleten' sibirskoi meditsiny. 2019;18(2):262-71 (in Russian)]. DOI:10.20538/1682-0363-2019-2-262–273
22. Papadopoulos NG, Bernstein JA, Demoly P, et al. Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report. Allergy. 2015;70(5):474-94. DOI:10.1111/all.12573
23. Hellings PW, Muraro A, Fokkens W, et al. A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress. Clin Transl Allergy. 2015;5:36. DOI:10.1186/s13601-015-0080-9
24. Клинические рекомендации. Аллергический ринит. Российская ассоциация аллергологов и клинических иммунологов; Национальная медицинская ассоциация оториноларингологов; Союз педиатров России. 2021. Режим доступа: https://www.pediatr-russia.ru/information/klin-rek/proekty-klinicheskikh-rekomendatsiy. Ссылка активна на 11.08.2021 (Clinical guidelines. Allergic rhinitis. Russian Association of Allergists and Clinical Immunologists; National Medical Association of Otorhinolaryngologists; Union of Pediatricians of Russia. 2021. Available at: https://www.pediatr-russia.ru/information/klin-rek/proekty-klinicheskikh-rekomendatsiy. Accessed: 11.08.2021 (in Russian)].
25. Brożek JL, Bousquet J, Agache I, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines – 2016 revision. J Allergy Clin Immunol. 2017;140(4):950-8. DOI:10.1016/j.jaci.2017.03.050
26. Pfaar O, Klimek L, Gerth van Wijk R. Clinically relevant outcome measures for new pharmacotherapy, allergen avoidance and immunotherapy trials in allergic rhinoconjunctivitis. Curr Opin Allergy Clin Immunol. 2015;15(3):197-203. DOI:10.1097/ACI.0000000000000164
27. Hellings PW, Muraro A, Fokkens W, et al. A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress. Clin Transl Allergy. 2015;5:36. DOI:10.1186/s13601-015-0080-9
28. Хаитов М.Р., Намазова-Баранова Л.С., Чучалин А.Г., и др. ARIA 2016: Современные направления оказания медицинской помощи больным аллергическим ринитом в свете требований прецизионной медицины. Российский аллергологический журнал. 2017;14(3):46-54 [Khaitov MR, Namazova-Baranova LS, Chuchalin AG, et al. Sovremennye napravleniia okazaniia meditsinskoi pomoshchi bol'nym allergicheskim rinitom v svete trebovanii pretsizionnoi meditsiny. Rossiiskii allergologicheskii zhurnal. 2017;14(3):46-54 (in Russian)]. DOI:10.36691/RJA312
29. Hox V, Lourijsen E, Jordens A, et al. Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clin Transl Allergy. 2020;10:1. DOI:10.1186/s13601-019-0303-6. Erratum in: Clin Transl Allergy. 2020;10:38. PMID: 31908763; PMCID: PMC6941282.
30. Mygind N. Local effect of intranasal beclomethasone dipropionate aerosol in hay fever. Br Med J. 1973;4(5890):464-6. DOI:10.1136/bmj.4.5890.464
31. Samoliński B, Nowicka A, Wojas O, et al. Intranasal glucocorticosteroids – not only in allergic rhinitis In the 40th anniversary of intranasal glucocorticosteroids' introduction. Otolaryngol Pol. 2014;68(2):51-64. DOI:10.1016/j.otpol.2013.12.003
32. Bachert C, Bousquet J, Hellings P. Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management. Clin Transl Allergy. 2018;8:25. DOI:10.1186/s13601-018-0210-2
33. Van As A, Bronsky E, Grossman J, et al. Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis. Ann Allergy. 1991;67(2 Pt. 1):156-62.
34. Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol. 1998;101(4 Pt. 2):S434-9. DOI:10.1016/s0091-6749(98)70155-1
35. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy. 2008;63(10):1292-300. DOI:10.1111/j.1398-9995.2008.01750.x
36. Сrim C, Pierre LN, Daley-Yates PT. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther. 2001;23(9):1339-54. DOI:10.1016/s0149-2918(01)80113-2
37. Bousquet J, Chanal I, Alquié MC, et al. Prevention of pollen rhinitis symptoms: comparison of fluticasone propionate aqueos nasal spray and disodium chromoglicate aqueous nasal spray. Allergy. 1993;48(5):327-33. DOI:10.1111/j.1398-9995.1993.tb02401.x
38. Vervloet D, Defougeres JK, Charpin D. Fluticasone propionate aqueous nasal spray versus cetirizine in seasonal rhinitis. J Allergy Clin Immunol. 1992;89:304.
39. Dolovich J, Wong AG, Chodirker WB, et al. Multicenter trial of fluticasone propionate aqueous nasal spray in ragweed allergic rhinitis. Ann Allergy. 1994;73(2):147-53. PMID: 8067598.
40. Géhanno P, Desfougeres JL. Fluticasone propionate aqueous nasal spray compared with oral loratadine in patients with seasonal allergic rhinitis. Allergy. 1997;52(4):445-50. DOI:10.1111/j.1398-9995.1997.tb01027.x
41. Storms WW. Treatment of seasonal allergic rhinitis with fluticasone propionate aqueous nasal spray: review of comparator studies. Allergy. 1995;50(23 Suppl.):25-9. DOI:10.1111/j.1398-9995.1995.tb02738.x
42. Small M, Piercy J, Demoly P, Marsden H. Burden of illness and quality of life in patients being treated for seasonal allergic rhinitis: a cohort survey. Clin Transl Allergy. 2013;3(1):33. DOI:10.1186/2045-7022-3-33
43. DeWester J, Philpot EE, Westlund RE, et al. The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc. 2003;24:331-7.
44. Berstein DI, Levy AL, Hamperl FC, et al. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy. 2004;34:952-7.
45. Лопатин А.С. Кортикостероидная терапия в лечении заболеваний носа и околоносовых пазух: исторические аспекты. Consilium Medicum. 2004;6(4):280-3 [Lopatin AS. Kortikosteroidnaia terapiia v lechenii zabolevanii nosa i okolonosovykh pazukh: istoricheskie aspekty. Consilium Medicum. 2004;6(4):280-3 (in Russian)].
46. Keith PK, Scadding GK. Are intranasal corticosteroids all equally consistent in managing ocular symptoms of seasonal allergic rhinitis? Curr Med Res Opin. 2009;25(8):2021-41. DOI:10.1185/03007990903094106
47. Ciprandi G, Canonica WG, Grosclaude M, et al. Effects of budesonide and fluticasone propionate in a placebocontrolled study on symptoms and quality of life in seasonal allergic rhinitis. Allergy. 2002;57:586-91.
48. Bielory L, Gross GN, Letierce A, et al. Ocular symptoms improvement from intranasal triamcinolone compared with placebo and intranasal fluticasone propionate: A meta-analysis. Ann Allergy Asthma Immunol. 2020;124(6):616-21.e3. DOI:10.1016/j.anai.2020.01.012.
49. Allen DB, Meltzer EO, Lemanske RF Jr., et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc. 2002;23(6):407-13.
50. Settipane RA, Kaliner MA. Chapter 14: Nonallergic rhinitis. Am J Rhinol Allergy. 2013; 27(Suppl. 1):S48-51.
51. Kaliner MA. Nonallergic rhinopathy (formerly known as vasomotor rhinitis). Immunol Allergy Clin North Am. 2011;31(3):441-55.
52. Singh U, Bernstein JA, Haar L, et al. Azelastine desensitization of transient receptor potential vanilloid 1: a potential mechanism explaining its therapeutic effect in nonallergic rhinitis. Am J Rhinol Allergy. 2014;28:215-24.
53. Астафьева Н.Г., Гамова И.В., Кобзев Д.Ю., и др. Нестероидные противовоспалительные препараты как причина обострения астмы и других респираторных заболеваний: диагностика и лечение (ч. 2). Лечащий врач. 2016;5:82-8 [Nesteroidnye protivovospalitel'nye preparaty kak prichina obostreniia astmy i drugikh respiratornykh zabolevanii: diagnostika i lechenie (ch. 2). Lechashchii vrach. 2016;5:82-8 (in Russian)].
54. Astafieva N, Kobzev D, Gamova I, et al. Efficacy and safety of fluticasone propionate and its generic among patients with nonallergic rhinopathy. Allergy. 2012;67 (Suppl. 96).
55. Резолюция совета экспертов «Актуализация клинических рекомендаций по острому риносинуситу и адаптация их к EPOS 2020». Режим доступа:
https://egispro.ru/wp-content/uploads/2020/12/rezolyucziya-soveta-eksper-.pdf. Ссылка активна на 11.08.2021 [Resolution of the Expert Council “Updating clinical guidelines for acute rhinosinusitis and adapting them to EPOS 2020”. Available at: https://egispro.ru/wp-content/uploads/2020/12/rezolyucziya-soveta-eksper-.pdf. Accessed: 11.08.2021 (in Russian)].
56. Crawford B, Stanford R, Wong AY, et al. Development of a questionnaire to assess experience and preference of intranasal corticosteroids in patients with allergic rhinitis. J Asthma Allergy. 2011;2:119-26.
57. Bachert C, Pawankar R, Zhang L, et al. ICON: chronic rhinosinusitis. World Allergy Organ J. 2014;7(1):25. DOI:10.1186/1939-4551-7-25
58. Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2013;131(6):1479-90. DOI:10.1016/j.jaci.2013.02.036
59. Grossman J, Banov C, Bronsky EA, et al. Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis. Pediatrics. 1993;92(4):594-9.
60. Ridolo E, Caminati M, Martignago I, et al. Allergic rhinitis: pharmacotherapy in pregnancy and old age. Expert Rev Clin Pharmacol. 2016;9(8):1081-9. DOI:10.1080/17512433.2016.1189324
61. Bozek A. Pharmacological Management of Allergic Rhinitis in the Elderly. Drugs Aging. 2017;34(1):21-8. DOI:10.1007/s40266-016-0425-7
62. Remien K, Bowman A. Fluticasone. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2021. PMID: 31194318.
63. McDonnell J, Weller K, Pien LC. Safety of Intranasal Steroids: an Updated Perspective. Curr Allergy Asthma Rep. 2020;20(11):69. DOI:10.1007/s11882-020-00960-2
64. Berger W, Sher E, Gawchik S, Fineman S. Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial. Allergy Asthma Proc. 2018;39(2):110-6. DOI:10.2500/aap.2018.39.4116
65. Ilyina NI, Edin AS, Astafieva NG, et al. Efficacy of a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate, Delivered in a Single Spray, for the Treatment of Seasonal Allergic Rhinitis: Results from Russia. Int Arch Allergy Immunol. 2019;178(3):255-63. DOI:10.1159/000494507
66. Klimek L, Berger WE, Bousquet J, et al. MP-AzeFlu in Moderate-to-Severe Allergic Rhinitis: A Literature Review. Int Arch Allergy Immunol. 2021:1-10. DOI:10.1159/000516417
67. Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: A practice parameter update. J Allergy Clin Immunol. 2020;146(4):721-67. DOI:10.1016/j.jaci.2020.07.007
68. Du K, Qing H, Zheng M, et al. Intranasal antihistamine is superior to oral H1 antihistamine as an add-on therapy to intranasal corticosteroid for treating allergic rhinitis. Ann Allergy Asthma Immunol. 2020;125(5):589-96.e3. DOI:10.1016/j.anai.2020.06.038
69. Bousquet J, Schunemann H, Togias A, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145:70-80.
70. Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021;11(3):213-739.
DOI:10.1002/alr.22741
2. Bousquet J, Schünemann HJ, Togias A, et al; Allergic Rhinitis and Its Impact on Asthma Working Group. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70-80.e3. DOI:10.1016/j.jaci.2019.06.049
3. Bousquet J, Schunemann HJ, Hellings PW, et al. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016;138(2):367-74. DOI:10.1016/j.jaci.2016.03.025
4. Bousquet J, Schünemann HJ, Hellings PW, et al; MASK study group. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016;138(2):367-74.e2. DOI:10.1016/j.jaci.2016.03.025
5. Fokkens W, Lund V, Hopkins HP, et al. EPOS2020: European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl. S29):1-464.
6. Global atlas of allergic rhinitis and chronic rhinosinusitis. Ed. CA Akdis, PW Hellings, I Agache, et al. Zurich, Switzerland: European Academy of Allergy and Clinical Immunology, 2015.
7. Papadopoulos NG, Bernstein JA, Demoly P, et al. Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report. Allergy. 2015;70(5):474-94. DOI:10.1111/all.12573
8. Brożek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines – 2016 Revision. J Allergy Clin Immunol. 2017;140(4):950-8. DOI:10.1016/j.jaci.2017.03.050
9. Allergicheskii rinit. Federal'nye klinicheskie rekomendatsii. Rossiiskii allergologicheskii zhurnal. 2018;4:43-53 (in Russian)
10. Allergic rhinitis. Clinical guidelines. Russian Association of Allergists and Clinical Immunologists; National Medical Association of Otorhinolaryngologists; Union of Pediatricians of Russia. 2021. Available at: https://www.pediatr-russia.ru/information/klin-rek/proekty-klinicheskikh-rekomendatsiy. Accessed: 11.08.2021 (in Russian)
11. Astaf'eva NG, Kobzev DIu, Gamova IV, et al. Mnogolikii rinit: sovremennyi vzgliad na diagnostiku i algoritm lecheniia. Lechashchii vrach. 2018;4:7-18 (in Russian)
12. Bousquet J, Schunemann HJ, Fonseca J, et al. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy. 2015;70:1372-92.
13. Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl. S29):1-464. DOI:10.4193/Rhin20.600
14. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl. 86):8-160. DOI:10.1111/j.1398-9995.2007.01620.x
15. Settipane RA, Kaliner MA. Nonallergic rhinitis. Am J Rhinol Allergy. 2013;27(Suppl. 1):S48-51.
16. Hellings PW, Klimek L, Cingi C, et al. Non-allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2017;72(11):1657-65. DOI:10.1111/all.13200
17. Poddighe D, Gelardi M, Licari A, et al. Non-allergic rhinitis in children: Epidemiological aspects, pathological features, diagnostic methodology and clinical management. World J Methodol. 2016;6(4):200-13. DOI:10.5662/wjm.v6.i4.200
18. Astaf'eva NG, Udovichenko EN, Gamova IV, et al. Allergicheskie i neallergicheskie rinity: sravnitel'naia kharakteristika (chast' 1). Lechashchii vrach. 2013;4:10-2 (in Russian)
19. Shamkina PA, Krivopalov AA, Ryazantsev SV, et al. Epidemiology of chronic rhinosinusitis. Sovremennye problemy nauki i obrazovaniia. 2019;3:152. Available at: https://science-education.ru/ru/article/view?id=28891. Accessed: 09.08.2021 (in Russian)
20. Acute rhinosinusitis: clinical guidelines. Ed. AS Lopatin. Moscow, 2017 (in Russian)
21. Tiufilin DS, Deev IA, Kobiakova OS, et al. Kontrol' allergicheskogo rinita: sovremennye instrumenty otsenki. Biulleten' sibirskoi meditsiny. 2019;18(2):262-71 (in Russian) DOI:10.20538/1682-0363-2019-2-262–273
22. Papadopoulos NG, Bernstein JA, Demoly P, et al. Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report. Allergy. 2015;70(5):474-94. DOI:10.1111/all.12573
23. Hellings PW, Muraro A, Fokkens W, et al. A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress. Clin Transl Allergy. 2015;5:36. DOI:10.1186/s13601-015-0080-9
24. Clinical guidelines. Allergic rhinitis. Russian Association of Allergists and Clinical Immunologists; National Medical Association of Otorhinolaryngologists; Union of Pediatricians of Russia. 2021. Available at: https://www.pediatr-russia.ru/information/klin-rek/proekty-klinicheskikh-rekomendatsiy. Accessed: 11.08.2021 (in Russian)
25. Brożek JL, Bousquet J, Agache I, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines – 2016 revision. J Allergy Clin Immunol. 2017;140(4):950-8. DOI:10.1016/j.jaci.2017.03.050
26. Pfaar O, Klimek L, Gerth van Wijk R. Clinically relevant outcome measures for new pharmacotherapy, allergen avoidance and immunotherapy trials in allergic rhinoconjunctivitis. Curr Opin Allergy Clin Immunol. 2015;15(3):197-203. DOI:10.1097/ACI.0000000000000164
27. Hellings PW, Muraro A, Fokkens W, et al. A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress. Clin Transl Allergy. 2015;5:36. DOI:10.1186/s13601-015-0080-9
28. Khaitov MR, Namazova-Baranova LS, Chuchalin AG, et al. Sovremennye napravleniia okazaniia meditsinskoi pomoshchi bol'nym allergicheskim rinitom v svete trebovanii pretsizionnoi meditsiny. Rossiiskii allergologicheskii zhurnal. 2017;14(3):46-54 (in Russian) DOI:10.36691/RJA312
29. Hox V, Lourijsen E, Jordens A, et al. Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clin Transl Allergy. 2020;10:1. DOI:10.1186/s13601-019-0303-6. Erratum in: Clin Transl Allergy. 2020;10:38. PMID: 31908763; PMCID: PMC6941282.
30. Mygind N. Local effect of intranasal beclomethasone dipropionate aerosol in hay fever. Br Med J. 1973;4(5890):464-6. DOI:10.1136/bmj.4.5890.464
31. Samoliński B, Nowicka A, Wojas O, et al. Intranasal glucocorticosteroids – not only in allergic rhinitis In the 40th anniversary of intranasal glucocorticosteroids' introduction. Otolaryngol Pol. 2014;68(2):51-64. DOI:10.1016/j.otpol.2013.12.003
32. Bachert C, Bousquet J, Hellings P. Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management. Clin Transl Allergy. 2018;8:25. DOI:10.1186/s13601-018-0210-2
33. Van As A, Bronsky E, Grossman J, et al. Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis. Ann Allergy. 1991;67(2 Pt. 1):156-62.
34. Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol. 1998;101(4 Pt. 2):S434-9. DOI:10.1016/s0091-6749(98)70155-1
35. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy. 2008;63(10):1292-300. DOI:10.1111/j.1398-9995.2008.01750.x
36. Сrim C, Pierre LN, Daley-Yates PT. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther. 2001;23(9):1339-54. DOI:10.1016/s0149-2918(01)80113-2
37. Bousquet J, Chanal I, Alquié MC, et al. Prevention of pollen rhinitis symptoms: comparison of fluticasone propionate aqueos nasal spray and disodium chromoglicate aqueous nasal spray. Allergy. 1993;48(5):327-33. DOI:10.1111/j.1398-9995.1993.tb02401.x
38. Vervloet D, Defougeres JK, Charpin D. Fluticasone propionate aqueous nasal spray versus cetirizine in seasonal rhinitis. J Allergy Clin Immunol. 1992;89:304.
39. Dolovich J, Wong AG, Chodirker WB, et al. Multicenter trial of fluticasone propionate aqueous nasal spray in ragweed allergic rhinitis. Ann Allergy. 1994;73(2):147-53. PMID: 8067598.
40. Géhanno P, Desfougeres JL. Fluticasone propionate aqueous nasal spray compared with oral loratadine in patients with seasonal allergic rhinitis. Allergy. 1997;52(4):445-50. DOI:10.1111/j.1398-9995.1997.tb01027.x
41. Storms WW. Treatment of seasonal allergic rhinitis with fluticasone propionate aqueous nasal spray: review of comparator studies. Allergy. 1995;50(23 Suppl.):25-9. DOI:10.1111/j.1398-9995.1995.tb02738.x
42. Small M, Piercy J, Demoly P, Marsden H. Burden of illness and quality of life in patients being treated for seasonal allergic rhinitis: a cohort survey. Clin Transl Allergy. 2013;3(1):33. DOI:10.1186/2045-7022-3-33
43. DeWester J, Philpot EE, Westlund RE, et al. The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc. 2003;24:331-7.
44. Berstein DI, Levy AL, Hamperl FC, et al. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy. 2004;34:952-7.
45. Lopatin AS. Kortikosteroidnaia terapiia v lechenii zabolevanii nosa i okolonosovykh pazukh: istoricheskie aspekty. Consilium Medicum. 2004;6(4):280-3 (in Russian)
46. Keith PK, Scadding GK. Are intranasal corticosteroids all equally consistent in managing ocular symptoms of seasonal allergic rhinitis? Curr Med Res Opin. 2009;25(8):2021-41. DOI:10.1185/03007990903094106
47. Ciprandi G, Canonica WG, Grosclaude M, et al. Effects of budesonide and fluticasone propionate in a placebocontrolled study on symptoms and quality of life in seasonal allergic rhinitis. Allergy. 2002;57:586-91.
48. Bielory L, Gross GN, Letierce A, et al. Ocular symptoms improvement from intranasal triamcinolone compared with placebo and intranasal fluticasone propionate: A meta-analysis. Ann Allergy Asthma Immunol. 2020;124(6):616-21.e3. DOI:10.1016/j.anai.2020.01.012.
49. Allen DB, Meltzer EO, Lemanske RF Jr., et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc. 2002;23(6):407-13.
50. Settipane RA, Kaliner MA. Chapter 14: Nonallergic rhinitis. Am J Rhinol Allergy. 2013; 27(Suppl. 1):S48-51.
51. Kaliner MA. Nonallergic rhinopathy (formerly known as vasomotor rhinitis). Immunol Allergy Clin North Am. 2011;31(3):441-55.
52. Singh U, Bernstein JA, Haar L, et al. Azelastine desensitization of transient receptor potential vanilloid 1: a potential mechanism explaining its therapeutic effect in nonallergic rhinitis. Am J Rhinol Allergy. 2014;28:215-24.
53. Nesteroidnye protivovospalitel'nye preparaty kak prichina obostreniia astmy i drugikh respiratornykh zabolevanii: diagnostika i lechenie (ch. 2). Lechashchii vrach. 2016;5:82-8 (in Russian)
54. Astafieva N, Kobzev D, Gamova I, et al. Efficacy and safety of fluticasone propionate and its generic among patients with nonallergic rhinopathy. Allergy. 2012;67 (Suppl. 96).
55. Resolution of the Expert Council “Updating clinical guidelines for acute rhinosinusitis and adapting them to EPOS 2020”. Available at: https://egispro.ru/wp-content/uploads/2020/12/rezolyucziya-soveta-eksper-.pdf. Accessed: 11.08.2021 (in Russian)
56. Crawford B, Stanford R, Wong AY, et al. Development of a questionnaire to assess experience and preference of intranasal corticosteroids in patients with allergic rhinitis. J Asthma Allergy. 2011;2:119-26.
57. Bachert C, Pawankar R, Zhang L, et al. ICON: chronic rhinosinusitis. World Allergy Organ J. 2014;7(1):25. DOI:10.1186/1939-4551-7-25
58. Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2013;131(6):1479-90. DOI:10.1016/j.jaci.2013.02.036
59. Grossman J, Banov C, Bronsky EA, et al. Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis. Pediatrics. 1993;92(4):594-9.
60. Ridolo E, Caminati M, Martignago I, et al. Allergic rhinitis: pharmacotherapy in pregnancy and old age. Expert Rev Clin Pharmacol. 2016;9(8):1081-9. DOI:10.1080/17512433.2016.1189324
61. Bozek A. Pharmacological Management of Allergic Rhinitis in the Elderly. Drugs Aging. 2017;34(1):21-8. DOI:10.1007/s40266-016-0425-7
62. Remien K, Bowman A. Fluticasone. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2021. PMID: 31194318.
63. McDonnell J, Weller K, Pien LC. Safety of Intranasal Steroids: an Updated Perspective. Curr Allergy Asthma Rep. 2020;20(11):69. DOI:10.1007/s11882-020-00960-2
64. Berger W, Sher E, Gawchik S, Fineman S. Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial. Allergy Asthma Proc. 2018;39(2):110-6. DOI:10.2500/aap.2018.39.4116
65. Ilyina NI, Edin AS, Astafieva NG, et al. Efficacy of a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate, Delivered in a Single Spray, for the Treatment of Seasonal Allergic Rhinitis: Results from Russia. Int Arch Allergy Immunol. 2019;178(3):255-63. DOI:10.1159/000494507
66. Klimek L, Berger WE, Bousquet J, et al. MP-AzeFlu in Moderate-to-Severe Allergic Rhinitis: A Literature Review. Int Arch Allergy Immunol. 2021:1-10. DOI:10.1159/000516417
67. Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: A practice parameter update. J Allergy Clin Immunol. 2020;146(4):721-67. DOI:10.1016/j.jaci.2020.07.007
68. Du K, Qing H, Zheng M, et al. Intranasal antihistamine is superior to oral H1 antihistamine as an add-on therapy to intranasal corticosteroid for treating allergic rhinitis. Ann Allergy Asthma Immunol. 2020;125(5):589-96.e3. DOI:10.1016/j.anai.2020.06.038
69. Bousquet J, Schunemann H, Togias A, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145:70-80.
70. Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021;11(3):213-739.
DOI:10.1002/alr.22741
2. Bousquet J, Schünemann HJ, Togias A, et al; Allergic Rhinitis and Its Impact on Asthma Working Group. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70-80.e3. DOI:10.1016/j.jaci.2019.06.049
3. Bousquet J, Schunemann HJ, Hellings PW, et al. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016;138(2):367-74. DOI:10.1016/j.jaci.2016.03.025
4. Bousquet J, Schünemann HJ, Hellings PW, et al; MASK study group. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016;138(2):367-74.e2. DOI:10.1016/j.jaci.2016.03.025
5. Fokkens W, Lund V, Hopkins HP, et al. EPOS2020: European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl. S29):1-464.
6. Global atlas of allergic rhinitis and chronic rhinosinusitis. Ed. CA Akdis, PW Hellings, I Agache, et al. Zurich, Switzerland: European Academy of Allergy and Clinical Immunology, 2015.
7. Papadopoulos NG, Bernstein JA, Demoly P, et al. Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report. Allergy. 2015;70(5):474-94. DOI:10.1111/all.12573
8. Brożek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines – 2016 Revision. J Allergy Clin Immunol. 2017;140(4):950-8. DOI:10.1016/j.jaci.2017.03.050
9. Аллергический ринит. Федеральные клинические рекомендации. Российский аллергологический журнал. 2018;4:43-53 [Allergicheskii rinit. Federal'nye klinicheskie rekomendatsii. Rossiiskii allergologicheskii zhurnal. 2018;4:43-53 (in Russian)].
10. Аллергический ринит. Клинические рекомендации. Российская ассоциация аллергологов и клинических иммунологов; Национальная медицинская ассоциация оториноларингологов; Союз педиатров России. 2021. Режим доступа: https://www.pediatr-russia.ru/information/klin-rek/proekty-klinicheskikh-rekomendatsiy. Ссылка активна на 11.08.2021 [Allergic rhinitis. Clinical guidelines. Russian Association of Allergists and Clinical Immunologists; National Medical Association of Otorhinolaryngologists; Union of Pediatricians of Russia. 2021. Available at: https://www.pediatr-russia.ru/information/klin-rek/proekty-klinicheskikh-rekomendatsiy. Accessed: 11.08.2021 (in Russian)].
11. Астафьева Н.Г., Кобзев Д.Ю., Гамова И.В., и др. Многоликий ринит: современный взгляд на диагностику и алгоритм лечения. Лечащий врач. 2018;4:7-18 [Astaf'eva NG, Kobzev DIu, Gamova IV, et al. Mnogolikii rinit: sovremennyi vzgliad na diagnostiku i algoritm lecheniia. Lechashchii vrach. 2018;4:7-18 (in Russian)].
12. Bousquet J, Schunemann HJ, Fonseca J, et al. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy. 2015;70:1372-92.
13. Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl. S29):1-464. DOI:10.4193/Rhin20.600
14. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl. 86):8-160. DOI:10.1111/j.1398-9995.2007.01620.x
15. Settipane RA, Kaliner MA. Nonallergic rhinitis. Am J Rhinol Allergy. 2013;27(Suppl. 1):S48-51.
16. Hellings PW, Klimek L, Cingi C, et al. Non-allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2017;72(11):1657-65. DOI:10.1111/all.13200
17. Poddighe D, Gelardi M, Licari A, et al. Non-allergic rhinitis in children: Epidemiological aspects, pathological features, diagnostic methodology and clinical management. World J Methodol. 2016;6(4):200-13. DOI:10.5662/wjm.v6.i4.200
18. Астафьева Н.Г., Удовиченко Е.Н., Гамова И.В., и др. Аллергические и неаллергические риниты: сравнительная характеристика (часть 1). Лечащий врач. 2013;4:10-2 [Astaf'eva NG, Udovichenko EN, Gamova IV, et al. Allergicheskie i neallergicheskie rinity: sravnitel'naia kharakteristika (chast' 1). Lechashchii vrach. 2013;4:10-2 (in Russian)].
19. Шамкина П.А., Кривопалов А.А., Рязанцев С.В., и др. Эпидемиология хронических риносинуситов. Современные проблемы науки и образования. 2019;3:152. Режим доступа: https://science-education.ru/ru/article/view?id=28891. Ссылка активна на 09.08.2021 [Shamkina PA, Krivopalov AA, Ryazantsev SV, et al. Epidemiology of chronic rhinosinusitis. Sovremennye problemy nauki i obrazovaniia. 2019;3:152. Available at: https://science-education.ru/ru/article/view?id=28891. Accessed: 09.08.2021 (in Russian)].
20. Острый риносинусит: клинические рекомендации. Под ред. А.С. Лопатина. М., 2017 [Acute rhinosinusitis: clinical guidelines. Ed. AS Lopatin. Moscow, 2017 (in Russian)].
21. Тюфилин Д.С., Деев И.А., Кобякова О.С., и др. Контроль аллергического ринита: современные инструменты оценки. Бюллетень сибирской медицины. 2019;18(2):262-71 [Tiufilin DS, Deev IA, Kobiakova OS, et al. Kontrol' allergicheskogo rinita: sovremennye instrumenty otsenki. Biulleten' sibirskoi meditsiny. 2019;18(2):262-71 (in Russian)]. DOI:10.20538/1682-0363-2019-2-262–273
22. Papadopoulos NG, Bernstein JA, Demoly P, et al. Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report. Allergy. 2015;70(5):474-94. DOI:10.1111/all.12573
23. Hellings PW, Muraro A, Fokkens W, et al. A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress. Clin Transl Allergy. 2015;5:36. DOI:10.1186/s13601-015-0080-9
24. Клинические рекомендации. Аллергический ринит. Российская ассоциация аллергологов и клинических иммунологов; Национальная медицинская ассоциация оториноларингологов; Союз педиатров России. 2021. Режим доступа: https://www.pediatr-russia.ru/information/klin-rek/proekty-klinicheskikh-rekomendatsiy. Ссылка активна на 11.08.2021 (Clinical guidelines. Allergic rhinitis. Russian Association of Allergists and Clinical Immunologists; National Medical Association of Otorhinolaryngologists; Union of Pediatricians of Russia. 2021. Available at: https://www.pediatr-russia.ru/information/klin-rek/proekty-klinicheskikh-rekomendatsiy. Accessed: 11.08.2021 (in Russian)].
25. Brożek JL, Bousquet J, Agache I, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines – 2016 revision. J Allergy Clin Immunol. 2017;140(4):950-8. DOI:10.1016/j.jaci.2017.03.050
26. Pfaar O, Klimek L, Gerth van Wijk R. Clinically relevant outcome measures for new pharmacotherapy, allergen avoidance and immunotherapy trials in allergic rhinoconjunctivitis. Curr Opin Allergy Clin Immunol. 2015;15(3):197-203. DOI:10.1097/ACI.0000000000000164
27. Hellings PW, Muraro A, Fokkens W, et al. A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress. Clin Transl Allergy. 2015;5:36. DOI:10.1186/s13601-015-0080-9
28. Хаитов М.Р., Намазова-Баранова Л.С., Чучалин А.Г., и др. ARIA 2016: Современные направления оказания медицинской помощи больным аллергическим ринитом в свете требований прецизионной медицины. Российский аллергологический журнал. 2017;14(3):46-54 [Khaitov MR, Namazova-Baranova LS, Chuchalin AG, et al. Sovremennye napravleniia okazaniia meditsinskoi pomoshchi bol'nym allergicheskim rinitom v svete trebovanii pretsizionnoi meditsiny. Rossiiskii allergologicheskii zhurnal. 2017;14(3):46-54 (in Russian)]. DOI:10.36691/RJA312
29. Hox V, Lourijsen E, Jordens A, et al. Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clin Transl Allergy. 2020;10:1. DOI:10.1186/s13601-019-0303-6. Erratum in: Clin Transl Allergy. 2020;10:38. PMID: 31908763; PMCID: PMC6941282.
30. Mygind N. Local effect of intranasal beclomethasone dipropionate aerosol in hay fever. Br Med J. 1973;4(5890):464-6. DOI:10.1136/bmj.4.5890.464
31. Samoliński B, Nowicka A, Wojas O, et al. Intranasal glucocorticosteroids – not only in allergic rhinitis In the 40th anniversary of intranasal glucocorticosteroids' introduction. Otolaryngol Pol. 2014;68(2):51-64. DOI:10.1016/j.otpol.2013.12.003
32. Bachert C, Bousquet J, Hellings P. Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management. Clin Transl Allergy. 2018;8:25. DOI:10.1186/s13601-018-0210-2
33. Van As A, Bronsky E, Grossman J, et al. Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis. Ann Allergy. 1991;67(2 Pt. 1):156-62.
34. Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol. 1998;101(4 Pt. 2):S434-9. DOI:10.1016/s0091-6749(98)70155-1
35. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy. 2008;63(10):1292-300. DOI:10.1111/j.1398-9995.2008.01750.x
36. Сrim C, Pierre LN, Daley-Yates PT. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther. 2001;23(9):1339-54. DOI:10.1016/s0149-2918(01)80113-2
37. Bousquet J, Chanal I, Alquié MC, et al. Prevention of pollen rhinitis symptoms: comparison of fluticasone propionate aqueos nasal spray and disodium chromoglicate aqueous nasal spray. Allergy. 1993;48(5):327-33. DOI:10.1111/j.1398-9995.1993.tb02401.x
38. Vervloet D, Defougeres JK, Charpin D. Fluticasone propionate aqueous nasal spray versus cetirizine in seasonal rhinitis. J Allergy Clin Immunol. 1992;89:304.
39. Dolovich J, Wong AG, Chodirker WB, et al. Multicenter trial of fluticasone propionate aqueous nasal spray in ragweed allergic rhinitis. Ann Allergy. 1994;73(2):147-53. PMID: 8067598.
40. Géhanno P, Desfougeres JL. Fluticasone propionate aqueous nasal spray compared with oral loratadine in patients with seasonal allergic rhinitis. Allergy. 1997;52(4):445-50. DOI:10.1111/j.1398-9995.1997.tb01027.x
41. Storms WW. Treatment of seasonal allergic rhinitis with fluticasone propionate aqueous nasal spray: review of comparator studies. Allergy. 1995;50(23 Suppl.):25-9. DOI:10.1111/j.1398-9995.1995.tb02738.x
42. Small M, Piercy J, Demoly P, Marsden H. Burden of illness and quality of life in patients being treated for seasonal allergic rhinitis: a cohort survey. Clin Transl Allergy. 2013;3(1):33. DOI:10.1186/2045-7022-3-33
43. DeWester J, Philpot EE, Westlund RE, et al. The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc. 2003;24:331-7.
44. Berstein DI, Levy AL, Hamperl FC, et al. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy. 2004;34:952-7.
45. Лопатин А.С. Кортикостероидная терапия в лечении заболеваний носа и околоносовых пазух: исторические аспекты. Consilium Medicum. 2004;6(4):280-3 [Lopatin AS. Kortikosteroidnaia terapiia v lechenii zabolevanii nosa i okolonosovykh pazukh: istoricheskie aspekty. Consilium Medicum. 2004;6(4):280-3 (in Russian)].
46. Keith PK, Scadding GK. Are intranasal corticosteroids all equally consistent in managing ocular symptoms of seasonal allergic rhinitis? Curr Med Res Opin. 2009;25(8):2021-41. DOI:10.1185/03007990903094106
47. Ciprandi G, Canonica WG, Grosclaude M, et al. Effects of budesonide and fluticasone propionate in a placebocontrolled study on symptoms and quality of life in seasonal allergic rhinitis. Allergy. 2002;57:586-91.
48. Bielory L, Gross GN, Letierce A, et al. Ocular symptoms improvement from intranasal triamcinolone compared with placebo and intranasal fluticasone propionate: A meta-analysis. Ann Allergy Asthma Immunol. 2020;124(6):616-21.e3. DOI:10.1016/j.anai.2020.01.012.
49. Allen DB, Meltzer EO, Lemanske RF Jr., et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc. 2002;23(6):407-13.
50. Settipane RA, Kaliner MA. Chapter 14: Nonallergic rhinitis. Am J Rhinol Allergy. 2013; 27(Suppl. 1):S48-51.
51. Kaliner MA. Nonallergic rhinopathy (formerly known as vasomotor rhinitis). Immunol Allergy Clin North Am. 2011;31(3):441-55.
52. Singh U, Bernstein JA, Haar L, et al. Azelastine desensitization of transient receptor potential vanilloid 1: a potential mechanism explaining its therapeutic effect in nonallergic rhinitis. Am J Rhinol Allergy. 2014;28:215-24.
53. Астафьева Н.Г., Гамова И.В., Кобзев Д.Ю., и др. Нестероидные противовоспалительные препараты как причина обострения астмы и других респираторных заболеваний: диагностика и лечение (ч. 2). Лечащий врач. 2016;5:82-8 [Nesteroidnye protivovospalitel'nye preparaty kak prichina obostreniia astmy i drugikh respiratornykh zabolevanii: diagnostika i lechenie (ch. 2). Lechashchii vrach. 2016;5:82-8 (in Russian)].
54. Astafieva N, Kobzev D, Gamova I, et al. Efficacy and safety of fluticasone propionate and its generic among patients with nonallergic rhinopathy. Allergy. 2012;67 (Suppl. 96).
55. Резолюция совета экспертов «Актуализация клинических рекомендаций по острому риносинуситу и адаптация их к EPOS 2020». Режим доступа:
https://egispro.ru/wp-content/uploads/2020/12/rezolyucziya-soveta-eksper-.pdf. Ссылка активна на 11.08.2021 [Resolution of the Expert Council “Updating clinical guidelines for acute rhinosinusitis and adapting them to EPOS 2020”. Available at: https://egispro.ru/wp-content/uploads/2020/12/rezolyucziya-soveta-eksper-.pdf. Accessed: 11.08.2021 (in Russian)].
56. Crawford B, Stanford R, Wong AY, et al. Development of a questionnaire to assess experience and preference of intranasal corticosteroids in patients with allergic rhinitis. J Asthma Allergy. 2011;2:119-26.
57. Bachert C, Pawankar R, Zhang L, et al. ICON: chronic rhinosinusitis. World Allergy Organ J. 2014;7(1):25. DOI:10.1186/1939-4551-7-25
58. Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2013;131(6):1479-90. DOI:10.1016/j.jaci.2013.02.036
59. Grossman J, Banov C, Bronsky EA, et al. Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis. Pediatrics. 1993;92(4):594-9.
60. Ridolo E, Caminati M, Martignago I, et al. Allergic rhinitis: pharmacotherapy in pregnancy and old age. Expert Rev Clin Pharmacol. 2016;9(8):1081-9. DOI:10.1080/17512433.2016.1189324
61. Bozek A. Pharmacological Management of Allergic Rhinitis in the Elderly. Drugs Aging. 2017;34(1):21-8. DOI:10.1007/s40266-016-0425-7
62. Remien K, Bowman A. Fluticasone. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2021. PMID: 31194318.
63. McDonnell J, Weller K, Pien LC. Safety of Intranasal Steroids: an Updated Perspective. Curr Allergy Asthma Rep. 2020;20(11):69. DOI:10.1007/s11882-020-00960-2
64. Berger W, Sher E, Gawchik S, Fineman S. Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial. Allergy Asthma Proc. 2018;39(2):110-6. DOI:10.2500/aap.2018.39.4116
65. Ilyina NI, Edin AS, Astafieva NG, et al. Efficacy of a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate, Delivered in a Single Spray, for the Treatment of Seasonal Allergic Rhinitis: Results from Russia. Int Arch Allergy Immunol. 2019;178(3):255-63. DOI:10.1159/000494507
66. Klimek L, Berger WE, Bousquet J, et al. MP-AzeFlu in Moderate-to-Severe Allergic Rhinitis: A Literature Review. Int Arch Allergy Immunol. 2021:1-10. DOI:10.1159/000516417
67. Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: A practice parameter update. J Allergy Clin Immunol. 2020;146(4):721-67. DOI:10.1016/j.jaci.2020.07.007
68. Du K, Qing H, Zheng M, et al. Intranasal antihistamine is superior to oral H1 antihistamine as an add-on therapy to intranasal corticosteroid for treating allergic rhinitis. Ann Allergy Asthma Immunol. 2020;125(5):589-96.e3. DOI:10.1016/j.anai.2020.06.038
69. Bousquet J, Schunemann H, Togias A, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145:70-80.
70. Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021;11(3):213-739.
DOI:10.1002/alr.22741
________________________________________________
2. Bousquet J, Schünemann HJ, Togias A, et al; Allergic Rhinitis and Its Impact on Asthma Working Group. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70-80.e3. DOI:10.1016/j.jaci.2019.06.049
3. Bousquet J, Schunemann HJ, Hellings PW, et al. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016;138(2):367-74. DOI:10.1016/j.jaci.2016.03.025
4. Bousquet J, Schünemann HJ, Hellings PW, et al; MASK study group. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016;138(2):367-74.e2. DOI:10.1016/j.jaci.2016.03.025
5. Fokkens W, Lund V, Hopkins HP, et al. EPOS2020: European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl. S29):1-464.
6. Global atlas of allergic rhinitis and chronic rhinosinusitis. Ed. CA Akdis, PW Hellings, I Agache, et al. Zurich, Switzerland: European Academy of Allergy and Clinical Immunology, 2015.
7. Papadopoulos NG, Bernstein JA, Demoly P, et al. Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report. Allergy. 2015;70(5):474-94. DOI:10.1111/all.12573
8. Brożek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines – 2016 Revision. J Allergy Clin Immunol. 2017;140(4):950-8. DOI:10.1016/j.jaci.2017.03.050
9. Allergicheskii rinit. Federal'nye klinicheskie rekomendatsii. Rossiiskii allergologicheskii zhurnal. 2018;4:43-53 (in Russian)
10. Allergic rhinitis. Clinical guidelines. Russian Association of Allergists and Clinical Immunologists; National Medical Association of Otorhinolaryngologists; Union of Pediatricians of Russia. 2021. Available at: https://www.pediatr-russia.ru/information/klin-rek/proekty-klinicheskikh-rekomendatsiy. Accessed: 11.08.2021 (in Russian)
11. Astaf'eva NG, Kobzev DIu, Gamova IV, et al. Mnogolikii rinit: sovremennyi vzgliad na diagnostiku i algoritm lecheniia. Lechashchii vrach. 2018;4:7-18 (in Russian)
12. Bousquet J, Schunemann HJ, Fonseca J, et al. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy. 2015;70:1372-92.
13. Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl. S29):1-464. DOI:10.4193/Rhin20.600
14. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl. 86):8-160. DOI:10.1111/j.1398-9995.2007.01620.x
15. Settipane RA, Kaliner MA. Nonallergic rhinitis. Am J Rhinol Allergy. 2013;27(Suppl. 1):S48-51.
16. Hellings PW, Klimek L, Cingi C, et al. Non-allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2017;72(11):1657-65. DOI:10.1111/all.13200
17. Poddighe D, Gelardi M, Licari A, et al. Non-allergic rhinitis in children: Epidemiological aspects, pathological features, diagnostic methodology and clinical management. World J Methodol. 2016;6(4):200-13. DOI:10.5662/wjm.v6.i4.200
18. Astaf'eva NG, Udovichenko EN, Gamova IV, et al. Allergicheskie i neallergicheskie rinity: sravnitel'naia kharakteristika (chast' 1). Lechashchii vrach. 2013;4:10-2 (in Russian)
19. Shamkina PA, Krivopalov AA, Ryazantsev SV, et al. Epidemiology of chronic rhinosinusitis. Sovremennye problemy nauki i obrazovaniia. 2019;3:152. Available at: https://science-education.ru/ru/article/view?id=28891. Accessed: 09.08.2021 (in Russian)
20. Acute rhinosinusitis: clinical guidelines. Ed. AS Lopatin. Moscow, 2017 (in Russian)
21. Tiufilin DS, Deev IA, Kobiakova OS, et al. Kontrol' allergicheskogo rinita: sovremennye instrumenty otsenki. Biulleten' sibirskoi meditsiny. 2019;18(2):262-71 (in Russian) DOI:10.20538/1682-0363-2019-2-262–273
22. Papadopoulos NG, Bernstein JA, Demoly P, et al. Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report. Allergy. 2015;70(5):474-94. DOI:10.1111/all.12573
23. Hellings PW, Muraro A, Fokkens W, et al. A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress. Clin Transl Allergy. 2015;5:36. DOI:10.1186/s13601-015-0080-9
24. Clinical guidelines. Allergic rhinitis. Russian Association of Allergists and Clinical Immunologists; National Medical Association of Otorhinolaryngologists; Union of Pediatricians of Russia. 2021. Available at: https://www.pediatr-russia.ru/information/klin-rek/proekty-klinicheskikh-rekomendatsiy. Accessed: 11.08.2021 (in Russian)
25. Brożek JL, Bousquet J, Agache I, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines – 2016 revision. J Allergy Clin Immunol. 2017;140(4):950-8. DOI:10.1016/j.jaci.2017.03.050
26. Pfaar O, Klimek L, Gerth van Wijk R. Clinically relevant outcome measures for new pharmacotherapy, allergen avoidance and immunotherapy trials in allergic rhinoconjunctivitis. Curr Opin Allergy Clin Immunol. 2015;15(3):197-203. DOI:10.1097/ACI.0000000000000164
27. Hellings PW, Muraro A, Fokkens W, et al. A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress. Clin Transl Allergy. 2015;5:36. DOI:10.1186/s13601-015-0080-9
28. Khaitov MR, Namazova-Baranova LS, Chuchalin AG, et al. Sovremennye napravleniia okazaniia meditsinskoi pomoshchi bol'nym allergicheskim rinitom v svete trebovanii pretsizionnoi meditsiny. Rossiiskii allergologicheskii zhurnal. 2017;14(3):46-54 (in Russian) DOI:10.36691/RJA312
29. Hox V, Lourijsen E, Jordens A, et al. Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clin Transl Allergy. 2020;10:1. DOI:10.1186/s13601-019-0303-6. Erratum in: Clin Transl Allergy. 2020;10:38. PMID: 31908763; PMCID: PMC6941282.
30. Mygind N. Local effect of intranasal beclomethasone dipropionate aerosol in hay fever. Br Med J. 1973;4(5890):464-6. DOI:10.1136/bmj.4.5890.464
31. Samoliński B, Nowicka A, Wojas O, et al. Intranasal glucocorticosteroids – not only in allergic rhinitis In the 40th anniversary of intranasal glucocorticosteroids' introduction. Otolaryngol Pol. 2014;68(2):51-64. DOI:10.1016/j.otpol.2013.12.003
32. Bachert C, Bousquet J, Hellings P. Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management. Clin Transl Allergy. 2018;8:25. DOI:10.1186/s13601-018-0210-2
33. Van As A, Bronsky E, Grossman J, et al. Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis. Ann Allergy. 1991;67(2 Pt. 1):156-62.
34. Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol. 1998;101(4 Pt. 2):S434-9. DOI:10.1016/s0091-6749(98)70155-1
35. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy. 2008;63(10):1292-300. DOI:10.1111/j.1398-9995.2008.01750.x
36. Сrim C, Pierre LN, Daley-Yates PT. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther. 2001;23(9):1339-54. DOI:10.1016/s0149-2918(01)80113-2
37. Bousquet J, Chanal I, Alquié MC, et al. Prevention of pollen rhinitis symptoms: comparison of fluticasone propionate aqueos nasal spray and disodium chromoglicate aqueous nasal spray. Allergy. 1993;48(5):327-33. DOI:10.1111/j.1398-9995.1993.tb02401.x
38. Vervloet D, Defougeres JK, Charpin D. Fluticasone propionate aqueous nasal spray versus cetirizine in seasonal rhinitis. J Allergy Clin Immunol. 1992;89:304.
39. Dolovich J, Wong AG, Chodirker WB, et al. Multicenter trial of fluticasone propionate aqueous nasal spray in ragweed allergic rhinitis. Ann Allergy. 1994;73(2):147-53. PMID: 8067598.
40. Géhanno P, Desfougeres JL. Fluticasone propionate aqueous nasal spray compared with oral loratadine in patients with seasonal allergic rhinitis. Allergy. 1997;52(4):445-50. DOI:10.1111/j.1398-9995.1997.tb01027.x
41. Storms WW. Treatment of seasonal allergic rhinitis with fluticasone propionate aqueous nasal spray: review of comparator studies. Allergy. 1995;50(23 Suppl.):25-9. DOI:10.1111/j.1398-9995.1995.tb02738.x
42. Small M, Piercy J, Demoly P, Marsden H. Burden of illness and quality of life in patients being treated for seasonal allergic rhinitis: a cohort survey. Clin Transl Allergy. 2013;3(1):33. DOI:10.1186/2045-7022-3-33
43. DeWester J, Philpot EE, Westlund RE, et al. The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc. 2003;24:331-7.
44. Berstein DI, Levy AL, Hamperl FC, et al. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy. 2004;34:952-7.
45. Lopatin AS. Kortikosteroidnaia terapiia v lechenii zabolevanii nosa i okolonosovykh pazukh: istoricheskie aspekty. Consilium Medicum. 2004;6(4):280-3 (in Russian)
46. Keith PK, Scadding GK. Are intranasal corticosteroids all equally consistent in managing ocular symptoms of seasonal allergic rhinitis? Curr Med Res Opin. 2009;25(8):2021-41. DOI:10.1185/03007990903094106
47. Ciprandi G, Canonica WG, Grosclaude M, et al. Effects of budesonide and fluticasone propionate in a placebocontrolled study on symptoms and quality of life in seasonal allergic rhinitis. Allergy. 2002;57:586-91.
48. Bielory L, Gross GN, Letierce A, et al. Ocular symptoms improvement from intranasal triamcinolone compared with placebo and intranasal fluticasone propionate: A meta-analysis. Ann Allergy Asthma Immunol. 2020;124(6):616-21.e3. DOI:10.1016/j.anai.2020.01.012.
49. Allen DB, Meltzer EO, Lemanske RF Jr., et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc. 2002;23(6):407-13.
50. Settipane RA, Kaliner MA. Chapter 14: Nonallergic rhinitis. Am J Rhinol Allergy. 2013; 27(Suppl. 1):S48-51.
51. Kaliner MA. Nonallergic rhinopathy (formerly known as vasomotor rhinitis). Immunol Allergy Clin North Am. 2011;31(3):441-55.
52. Singh U, Bernstein JA, Haar L, et al. Azelastine desensitization of transient receptor potential vanilloid 1: a potential mechanism explaining its therapeutic effect in nonallergic rhinitis. Am J Rhinol Allergy. 2014;28:215-24.
53. Nesteroidnye protivovospalitel'nye preparaty kak prichina obostreniia astmy i drugikh respiratornykh zabolevanii: diagnostika i lechenie (ch. 2). Lechashchii vrach. 2016;5:82-8 (in Russian)
54. Astafieva N, Kobzev D, Gamova I, et al. Efficacy and safety of fluticasone propionate and its generic among patients with nonallergic rhinopathy. Allergy. 2012;67 (Suppl. 96).
55. Resolution of the Expert Council “Updating clinical guidelines for acute rhinosinusitis and adapting them to EPOS 2020”. Available at: https://egispro.ru/wp-content/uploads/2020/12/rezolyucziya-soveta-eksper-.pdf. Accessed: 11.08.2021 (in Russian)
56. Crawford B, Stanford R, Wong AY, et al. Development of a questionnaire to assess experience and preference of intranasal corticosteroids in patients with allergic rhinitis. J Asthma Allergy. 2011;2:119-26.
57. Bachert C, Pawankar R, Zhang L, et al. ICON: chronic rhinosinusitis. World Allergy Organ J. 2014;7(1):25. DOI:10.1186/1939-4551-7-25
58. Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2013;131(6):1479-90. DOI:10.1016/j.jaci.2013.02.036
59. Grossman J, Banov C, Bronsky EA, et al. Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis. Pediatrics. 1993;92(4):594-9.
60. Ridolo E, Caminati M, Martignago I, et al. Allergic rhinitis: pharmacotherapy in pregnancy and old age. Expert Rev Clin Pharmacol. 2016;9(8):1081-9. DOI:10.1080/17512433.2016.1189324
61. Bozek A. Pharmacological Management of Allergic Rhinitis in the Elderly. Drugs Aging. 2017;34(1):21-8. DOI:10.1007/s40266-016-0425-7
62. Remien K, Bowman A. Fluticasone. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2021. PMID: 31194318.
63. McDonnell J, Weller K, Pien LC. Safety of Intranasal Steroids: an Updated Perspective. Curr Allergy Asthma Rep. 2020;20(11):69. DOI:10.1007/s11882-020-00960-2
64. Berger W, Sher E, Gawchik S, Fineman S. Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial. Allergy Asthma Proc. 2018;39(2):110-6. DOI:10.2500/aap.2018.39.4116
65. Ilyina NI, Edin AS, Astafieva NG, et al. Efficacy of a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate, Delivered in a Single Spray, for the Treatment of Seasonal Allergic Rhinitis: Results from Russia. Int Arch Allergy Immunol. 2019;178(3):255-63. DOI:10.1159/000494507
66. Klimek L, Berger WE, Bousquet J, et al. MP-AzeFlu in Moderate-to-Severe Allergic Rhinitis: A Literature Review. Int Arch Allergy Immunol. 2021:1-10. DOI:10.1159/000516417
67. Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: A practice parameter update. J Allergy Clin Immunol. 2020;146(4):721-67. DOI:10.1016/j.jaci.2020.07.007
68. Du K, Qing H, Zheng M, et al. Intranasal antihistamine is superior to oral H1 antihistamine as an add-on therapy to intranasal corticosteroid for treating allergic rhinitis. Ann Allergy Asthma Immunol. 2020;125(5):589-96.e3. DOI:10.1016/j.anai.2020.06.038
69. Bousquet J, Schunemann H, Togias A, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145:70-80.
70. Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021;11(3):213-739.
DOI:10.1002/alr.22741
Авторы
Н.Г. Астафьева*1, И.В. Гамова1, Д.Ю. Кобзев2, И.А. Перфилова1, Е.Н. Удовиченко1, Л.В. Алешина1
1 ФГБОУ ВО «Саратовский государственный медицинский университет им. В.И. Разумовского» Минздрава России, Саратов, Россия;
2 Лидс Тринити университет, Школа здравоохранения и социальных наук, Великобритания
*astang@mail.ru
1 Razumovsky Saratov State Medical University, Saratov, Russia;
2 Leeds Trinity University, School of Health and Social Sciences, UK
*astang@mail.ru
1 ФГБОУ ВО «Саратовский государственный медицинский университет им. В.И. Разумовского» Минздрава России, Саратов, Россия;
2 Лидс Тринити университет, Школа здравоохранения и социальных наук, Великобритания
*astang@mail.ru
________________________________________________
1 Razumovsky Saratov State Medical University, Saratov, Russia;
2 Leeds Trinity University, School of Health and Social Sciences, UK
*astang@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.